"The
Report PharmaPoint: Ulcerative Colitis - Global Drug Forecast and
Market Analysis to 2022 - Event-Driven Update provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
The US presages the slow uptake
of these products in this market, which could limit their
availability, and consequently, inhibit the growth of the UC market.
Another
key event affecting the UC market is the anticipated launch of
biosimilars, given that the patent expiry of the UC blockbusters,
Remicade and Humira are set to expire in the US in 2018 and 2016,
respectively.
Overall,
major barriers to the growth of the UC market include -
-
Remicade and Humira losing patent protection in the mid-forecast
-
Austerity measures favoring generic prescribing
-
Biosimilars are predicted to face low uptake due to the lack of
regulatory guidelines in some markets, such as the US
View Report At
:http://www.marketresearchreports.biz/analysis/235638
Highlights
Key Questions Answered
- How will the UC market (sales
and patient numbers) evolve over the 10-year forecast period from
2012 to 2022?
- How will the launch of the
first-in-class Entyvio change the landscape of the UC market?
- Which brands and specific
drug classes did physicians select for their UC patients in 2012 and
how do they foresee their prescribing behavior evolving over the next
five years?
- How will the launch of
late-stage pipeline therapies such as etrolizumab and Kappaproct
shape the future treatment landscape?
- What are the remaining unmet
needs and opportunities for drug developers within the UC market?
Key Findings
- The UC market has
predominantly been driven by two TNF blockers, namely J&Js
Remicade and AbbVies Humira. Although these TNF blockers have
monopolized the UC market for almost a decade, the balance is about
to be tipped, with Takedas Entyvio and J&Js Simponi launch in
2014, stealing market share from Humira and Remicade.
- Remicade and Humira will also
be hit by their respective loss of patent protection in 2018 (US),
2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a
biosimilar to Remicade, Celltrions Remsima, which will be marketed by
Hospira under the brand name Inflectra in the EU. Due to lack of
regulatory guidelines and the current debate about indication
extrapolation for biosimilars based on a clinical trial in one
indication, initial biosimilar uptake will be low, but by the end of
the forecast period, in 2022 infliximab, adalimumab and golimumab
biosimilars are forecast to become an established part of the UC
market.
- During the coming decade,
Europe is expecting the approval and launch of a UC colectomy rescue
therapy, InDex Pharmaceuticals Kappaproct. Kappaproct is targeting a
small patient population group, but due to the involvement of key
gastroenterologists in the development of this therapy, it will
likely be welcomed for use in this new treatment setting, which has
never been addressed before by a pharmaceutical product. In addition,
Pfizers Xeljanz is expected to face low uptake post its estimated
launch in 2017, owing to the controversy surrounding its rejection by
the EMA for its primary indication, rheumatoid arthritis.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/235638
Scope
Overview of UC, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
current treatment options.
- Annualized UC therapeutics
market revenue, annual cost of therapy and treatment usage pattern
data from 2012 to 2022.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, and implications for the UC therapeutics markets.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, and detailed analysis of late stage
pipeline drugs.
- Analysis of the current and
future market competition in the global UC therapeutics markets.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
- Develop and design
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global UC
therapeutics markets.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global UC
therapeutics markets in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global UC therapeutics markets from 2012-2022.
- Organize sales and marketing
efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and
strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and
Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Symptoms 31
3.2.1 Quality of Life 32
4 Epidemiology 33
4.1 Disease Background 33
4.2 Risk Factors and
Comorbidities 34
4.2.1 Being Caucasian and
Jewish can increase the risk of UC by almost 37 times 35
4.2.2 A family history of UC in
first-degree relatives can increase the risk of the disease by almost
three-fold 35
4.2.3 Current smokers have a
lower risk of developing UC than former smokers or never smokers 36
4.3 Global Trends 37
4.3.1 US 38
4.3.2 5EU 40
4.3.3 Japan 43
4.3.4 Canada 44
4.3.5 China 46
4.3.6 India 48
4.4 Forecast Methodology 48
4.4.1 Sources Used 51
4.4.2 Sources Not Used 57
4.4.3 Forecast Assumptions and
Methods 57
4.5 Epidemiological Forecast of
UC (2012-2022) 63
4.5.1 Incident Cases of UC 63
4.5.2 Age-Specific Incident
Cases of UC 65
4.5.3 Sex-Specific Incident
Cases of UC 67
4.5.4 Age-Standardized
Incidence Rates 68
4.6 Epidemiological Forecast
for UC Prevalent Cases (2012-2022) 69
4.6.1 Prevalent Cases of UC 69
4.6.2 Age-Specific Prevalent
Cases of UC 71
4.6.3 Sex-Specific Prevalent
Cases of UC 73
4.6.4 Age-Standardized
Prevalence Rate of UC in All Markets 75
4.7 Discussion 76
4.7.1 Epidemiological Forecast
Insight 76
4.7.2 Limitations of the
Analysis 77
4.7.3 Strengths of the Analysis
78
5 Disease Management 79
5.1 Diagnosis and Treatment
Overview 79
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
